• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Ahead of the Curve: Pharm Exec Profiles Five Recent Drug Launches

Pharmaceutical ExecutivePharmaceutical Executive: September 2023
Volume 43
Issue 9

Pharm Exec’s latest selections of notable biopharma brand launches—some with novel preemptive approaches—highlight products that are paving uncharted paths across a diverse disease landscape.

Ahead of the curve

Follow the links below to read about each product:

Camzyos (Bristol Myers Squibb)

Enhertu (Daiichi Sankyo, AstraZeneca)

Rebyota (Ferring Pharmaceuticals)

Sunlenca (Gilead Sciences)

Tzield (Provention Bio, a Sanofi company)

Selections were made by Pharmaceutical Executive's editorial staff, with close input from Editorial Advisory Board members.

Related Videos
Related Content